Paul Friedman

Paul A. Friedman is Chairman at Prelude Therapeutics, Inc. since 2016.
Member of the American Society for Clinical Investigation, the American Society for Biochemistry & Molecular Biology, Inc., and the American Society for Pharmacology & Experimental Therapeutic.
Formerly Director at Bausch & Lomb, Inc. from 2004 to 2007.
Independent Director at Incyte Corp.
from 2014 to 2021.
Independent Director at Alexion Pharmaceuticals, Inc. from 2017 to 2021.
Independent Director at Auxilium Pharmaceuticals LLC from 2011 to 2015.
Director at Sirtris Pharmaceuticals, Inc. in 2008.
Independent Director at Synta Pharmaceuticals Corp.
from 2014 to 2016.
Director at Gliknik, Inc. in 2013.
Independent Director at Navitor Pharmaceuticals, Inc. Director at Cerulean Pharma, Inc. from 2016 to 2017.
Independent Director at Durata Therapeutics, Inc. in 2014.
Independent Director at Verastem, Inc. from 2015 to 2017.
Director at Madrigal Pharmaceuticals, Inc. from 2023 to 2026.
President-Research & Development at DuPont Merck Pharmaceutical Co. from 1994 to 1998.
Senior Vice President at Merck Research Laboratories Massachusetts LLC from 1991 to 1994.
President at DuPont Pharmaceuticals Research Laboratories from 1998 to 2001.
Associate Professor-Medicine & Pharmacology at Harvard Medical School.
Education includes undergraduate degree from Princeton University and doctorate from Harvard Medical School.